NeuroDawn Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 100

Employees

  • Latest Deal Type
  • Series C

  • Investors
  • 15

NeuroDawn General Information

Description

Developer of central nervous system drugs designed to treat neurological diseases. The company utilizes an internal research and development platform integrating chemical synthesis, biological screening, chemistry, manufacturing and control development, drug metabolism and pharmacokinetics research, in vivo pharmacology research, and toxicology research, enabling medical professionals to treat patients with strokes, alzheimer's disease, and neuropathic pain.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building A3, Tianyin Health Innovation Park
  • Number 2222 Gezhi Road, Jiangning District
  • Nanjing, Jiangsu 210000
  • China
+86 025
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Building A3, Tianyin Health Innovation Park
  • Number 2222 Gezhi Road, Jiangning District
  • Nanjing, Jiangsu 210000
  • China
+86 025

NeuroDawn Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroDawn Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 31-Oct-2024 Completed Generating Revenue
6. Secondary Transaction - Private 30-Sep-2024 Completed Generating Revenue
5. Early Stage VC (Series B1) 12-Jan-2024 Completed Generating Revenue
4. Early Stage VC (Series B) 10-Nov-2023 Completed Generating Revenue
3. Early Stage VC (Series A1) 06-Feb-2023 Completed Generating Revenue
2. Early Stage VC 22-Jul-2022 $10.8M Completed Generating Revenue
1. Early Stage VC (Series A) 12-Aug-2021 $10.8M $10.8M Completed Generating Revenue
To view NeuroDawn’s complete valuation and funding history, request access »

NeuroDawn Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroDawn Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Shengshi Hongming Investment Fund Management Fund of Funds Minority
Nanjing Innovation Capital Group Venture Capital Minority
Nanjing Jiangning Science and Technology Venture Capital Group Government Minority
Fuzhou Rongtou Investment Government Minority
Chunxin Capital Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

NeuroDawn Investments (1)

NeuroDawn’s most recent deal was a Corporate with Ruichu. The deal was made on 14-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ruichu 14-Oct-2021 Corporate Drug Discovery
To view NeuroDawn’s complete investments history, request access »

NeuroDawn FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process